Bristol-Myers Squibb raised FY 2025 guidance, with operating EPS targeted at $6.40–$6.60 and net sales above consensus. Click here to find out why BMY is a Buy.

Ichor Holdings (ICHR) is rated BUY, with fundamentals expected to improve in 2026 and a bottoming share price creating an attractive entry point. ICHR's new CEO is focused on operational discipline ...

In business, the power of individual leaders is an inherently hard thing to measure. It’s subjective, and it fluctuates on ...

Software vendors and logistics providers agree that the latest artificial intelligence (AI) agents hold tremendous potential ...

HEPA Filters: Our favorite cordless vacuums feature HEPA filters, which are designed to capture even the smallest of particles and allergens (usually around 99.97%). This filtration system ensures ...